Background: Inhibition of human carcinomas has previously been linked to vitamin D due to its effects on cancer cell proliferation, migration, angiogenesis, and apoptosis induction. The anticancer activity of vitamin D has been confirmed by several studies, which have shown that increased cancer incidence is associated with decreased vitamin D and that dietary supplementation of vitamin D slows down the growth of xenografted tumors in mice. Vitamin D inhibits the growth of cancer cells by the induction of apoptosis as well as by arresting the cells at the G0/G1 (or) G2/M phase of the cell cycle. Aim and Key Scientific Concepts of the Review: The purpose of this article is to thoroughly review the existing information and discuss and debate to conclude whether vitamin D could be used as an agent to prevent/treat cancers. The existing empirical data have demonstrated that vitamin D can also work in the absence of vitamin D receptors (VDRs), indicating the presence of multiple mechanisms of action for this sunshine vitamin. Polymorphism in the VDR is known to play a key role in tumor cell metastasis and drug resistance. Although there is evidence that vitamin D has both therapeutic and cancer-preventive properties, numerous uncertainties and concerns regarding its use in cancer treatment still exist. These include (a) increased calcium levels in individuals receiving therapeutic doses of vitamin D to suppress the growth of cancer cells; (b) hyperglycemia induction in certain vitamin D-treated study participants; (c) a dearth of evidence showing preventive or therapeutic benefits of cancer in clinical trials; (d) very weak support from proof-of-principle studies; and (e) the inability of vitamin D alone to treat advanced cancers. Addressing these concerns, more potent and less toxic vitamin D analogs have been created, and these are presently undergoing clinical trial evaluation. To provide key information regarding the functions of vitamin D and VDRs, this review provided details of significant advancements in the functional analysis of vitamin D and its analogs and VDR polymorphisms associated with cancers.
Hyperglycemia contributes to the development of cognition impairment and related disorders, induces oxidative stress in neuronal cells; thereby, impairs normal signaling mechanisms involved in cognition processes. Studies have shown a significant decrease in the vitamin D in individuals with hyperglycemia and cognition impairment. But whether supplementing vitamin D has any beneficiary impact on mitigating hyperglycemia-induced cognition impairment is unknown. We have first tested the impact of hyperglycemia on the induction of cognition deficiency in a zebrafish model. Next, the molecular mechanisms related to oxidative stress, which are deregulated in hyperglycemic zebrafish brains, have been explored. Subsequently, the impact of supplementing the water with vitamin D and a known activator of nuclear factor erythroid-2 related factor 2 (Nrf2) i.e., sulforaphane (SFN) on learning and memory functions were assessed. We showed a significant increase in the oxidative stress in the brain tissue of zebrafish residing in hyperglycemic water (111 mM glucose). Addition of vitamin D and SFN increased Nrf2, but differentially modulated its target genes (NQO1, SOD, GPx etc) activity in zebrafish and neuronal cell lines thereby improved the hyperglycemia-induced decline of cognition impairment. Mechanistically, vitamin D binds to the Keap1 protein; thereby, interfering with its binding to Nrf2, which leads to the activation of antioxidant mechanisms in the cells. In summary, reducing the oxidative stress through vitamin D treatment is a possible option for controlling the cognition impairment in diabetic population, but studies testing this possibility in clinical trials are currently needed.
Background: Disorders of mental health are known to affect cognitive functions, hence called as cognitive disorders. Impaired glucose metabolism, insulin resistance, vitamin-D deficiency and oxidative stress are some of the key early events reported to be involved in the pathogenesis of most common cognitive disorders, which include Alzheimer’s disease. Type-2 diabetes mellitus (T2DM) is one of the known contributing factors of cognitive impairment and dementia. Methods: A cross sectional study was carried out in 145 subjects, who were assessed for cognitive function by modified mini mental status examination (3MS). In addition, measurement of fasting blood sugar (FBS), fasting insulin, HbA1c, lipid profile, vitamin D and oxidative markers was performed. Participants were divided into different groups based on (a) vitamin D insufficiency and sufficiency; (b) diabetic and non-diabetic with and without cognitive impairment. Results: The study included a total of 145 subjects; 51 males and 94 females and the mean age was 68.24±9.70 years. Among diabetics with vitamin D insufficiency, 35 subjects (71.43%) had cognitive impairment, but, among non-diabetics with vitamin D insufficiency, 27 subjects (62.79%) had cognitive impairment. Chi square test showed no significant association between diabetes, vitamin D insufficiency and cognitive impairment. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) levels were non-significantly lower in cognition-impaired subjects, when compared to cognition normal subjects in diabetics with vitamin D insufficiency. Conclusion: Our study showed that cognitive impairment is more predominant in individuals with diabetes. However, our study did not find any significant relationship between T2DM, vitamin D deficiency, cognitive impairment, and oxidative stress. A significant association was found only with GPx and 3MSE score in vitamin D insufficient non-diabetics.
Background: In vitro cell culture is essential for elucidating various signaling mechanisms and screening pharmacological agents to assess their safety and efficacy. However, cell proliferation and survival in culture can be significantly influenced by variations in the composition of the culture medium. For instance, variations in glucose and fetal bovine serum (FBS) concentrations can impact cell viability. Despite this, only a few studies have examined the impact of varied FBS and glucose concentrations in culture media on cell viability. Objective: This study investigated the mechanisms and cellular effects of glucose and FBS deprivation in glioblastoma cell lines. Methods: We systematically evaluated the impact of FBS and glucose deprivation on the proliferation and survival of rat C6 and human U-87 MG glioblastoma cell lines. Results: Glucose deprivation (0 mg/dL) significantly reduced the viability of C6 cells and moderately lowered the viability of U-87 MG cells, with partial recovery upon glucose supplementation (100 mg/dL, 400 mg/dL). Notably, FBS deprivation (0%) exerted a more profound effect, inducing the accumulation of reactive oxygen species and extensive cell death in both cell lines. Restoration of FBS (1, 2, 4, 6, 8, and 10%) recovered cell viability and reduced oxidative stress. Furthermore, both glucose and FBS deprivation altered antioxidant enzyme expression and mitochondrial function. Glucose and FBS deprivation also differentially affected protein kinase B phosphorylation, suggesting metabolic stress-induced signaling modulation. Conclusion: These findings highlight the differential responses of glioblastoma cells to glucose and FBS deprivation and underscore the importance of standardizing culture conditions, especially serum and glucose levels, when designing experiments involving glioblastoma cells.
Introduction: Vitamin D status has been investigated as a modifiable risk factor with cognitive decline. However, studies pertaining to this remain inconsistent across populations, and there are fewer studies associating vitamin D status, cognitive decline, amyloid markers and oxidative stress markers in older adults. Therefore, this study was conducted to analyze the association between these parameters. Methodology: This cross-sectional study included 145 older adults aged between 51 and 80 years. Participants were categorized based on serum vitamin D levels into sufficient (n = 53), insufficient (n = 61), and deficient (n = 31) groups. Cognitive performance was assessed using the Modified Mini Mental State (3MS) test. Plasma levels of Aβ 1-40 and Aβ 1-42 and oxidative stress markers (TBARS, GPx, SOD) were measured. Statistical analysis was performed using ANOVA and Spearman’s correlation. Results: Results showed that the vitamin D concentrations did not differ significantly between cognitively impaired and normal individuals within vitamin D strata (vitamin D sufficient, insufficient and deficient groups). Plasma Aβ 1-40 levels were significantly elevated in cognitively impaired participants across all vitamin D groups. A reduced Aβ 1-42/Aβ 1-40 ratio was observed in sufficient and insufficient Vitamin D groups. Additionally, GPx levels were significantly higher in the vitamin D-deficient group. Correlation analysis showed that 3MS scores were negatively associated with age (r = −0.2607, p = 0.0015), Aβ 1-40 (r = −0.4016, p = 0.0001), and Aβ 1-42 (r = −0.3025, p = 0.0002), and positively correlated with Aβ 1-42/Aβ 1-40 ratio (r = 0.2176, p = 0.0086). Conclusions: These findings suggest that cognitive impairment in older adults is strongly associated with amyloid burden, oxidative stress, and age, whereas vitamin D status was not directly correlated with cognitive performance in this cohort.